Navigation Links
Results of DUTCH PEERS (TWENTE II) trial reported at TCT 2013
Date:10/31/2013

SAN FRANCISCO, CA October 31, 2013 Results of the DUTCH PEERS (TWENTE II) clinical trial demonstrate comparable safety and efficacy of two third-generation permanent polymer-based drug-eluting stents with low rates of adverse clinical events and establish the non-inferiority of the newest zotarolimus-eluting stent. The findings were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Third-generation permanent polymer-based drug-eluting stents (DES) with novel flexible designs were developed to improve stent deliverability in challenging anatomical lesions and to improve stent alignment within the vessel wall, while maintaining the anti-restenotic potential of newer generation DES systems. DUTCH PEERS (TWENTE II) follows the TWENTE trial, which was presented at TCT 2011 and examined second-generation drug-eluting stents with the same drugs and coatings but different stent platforms.

DUTCH PEERS was a multicenter, prospective, single-blinded, randomized controlled study in patients requiring percutaneous coronary interventions (PCI) with DES implantation. The study was performed in four PCI centers in the Netherlands (Thoraxcentrum Twente, Enschede; Rijnstate Hospital, Arnhem; Scheper Hospital, Emmen; Medical Center Alkmaar, Alkmaar). The primary endpoint was the composite target vessel failure (TVF) at one-year, defined as cardiac death, target vessel revascularization, or myocardial infarction (MI) attributable to the target vessel or not attributable to another vessel.

A total of 1,811 patients were randomly assigned to treatment with third-generation cobalt-chromium zotarolimus-eluting stents (906 patients; 1,205 lesions) or platinum-chromium everolimus-eluting stents (905 patients; 1,166 lesions). The study populat
'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. False-Positive Mammogram Results May Turn Out Not to Be: Study
2. Good intentions bring mixed results for Haitis disabled people
3. Presentation of 1-year IVAN and 2-year CATT study results
4. Groundbreaking Nigeria summit results in major commitment to reduce child deaths
5. Surprising results for use of dialysis for kidney failure in developing world
6. Stem Cell Study Shows Promising Results Against Heart Failure
7. Automated insulin dosage titration system demonstrates positive clinical study results
8. Quality of care, other issues may cause worse results in black prostate cancer surgery patients
9. Tight Blood-Sugar Control Shows Mixed Results for Health of Kidneys: Study
10. ACP-New York State Chapter partnership results in patient safety organization recognition
11. Long-term testosterone treatment for men results in reduced weight and waist size
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Since 1978, the number of black males ... new publication released today by the AAMC (Association of American Medical Colleges). , ... past three decades, the number of black male applicants to medical school dropped to ...
(Date:8/3/2015)... ... ... They know every second counts. And when it comes to stroke, the ... best care in the nation. For the past two months, the stroke team led ... time in the country. During the months of June and July, it took the ...
(Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... R&D services to contract research organisations (CROs) for a slew of benefits, allowing ... global research and operations, boost quality with cost-effective utilisation of resources, get access ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in Los Angeles , ... Most people know that general health emergencies, such as broken arms or a heart ... know where to turn to during a dental emergency. This is important, because dental ...
(Date:8/3/2015)... ... 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and ... Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker ... the Company’s presentation may be accessed via the investor relations section of the Company’s ...
Breaking Medicine News(10 mins):Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... on a baby inside the womb. The baby, Grace, underwent the ... discharged on Friday after the successful completion of the surgery. ... left heart syndrome (HLHS) inside the womb. When she was 30 ... November 7, 2005. ,She was born on January 10 ...
... in a hospital at Brisbane a patient had to be ... attacked and was in serious condition, attention could not be ... Hospital, where emergency services are scarce due to shortage of ... operational from 8am to 6pm every day. ,The ...
... that it intends to fast track its inhaled insulin Exubera ... and Drug Administration // and the European Commission last ... and Nektar Therapeutics. ,It is a relatively harmless ... syringes are needed. "Until today, patients with diabetes who need ...
... successfully reached the Vinson Massif summit, one of Antarctica's ... and was successfully completed on January 19th after eight ... was a strong, healthy athlete who was later diagnosed ... of the disease he lost 80 pounds and his ...
... on the pregnant women. , It ... people are in search for a remedy for it. // ... pregnant women approaching the health care centers for a treatment related to ... to include new information about the management of stress during pregnancy. ...
... reported to be infected with the H5N1 strain, making this ... country, even though the EU rules remain suspended in the ... infection was detected attracts as many as 1 million UK ... is said to be the same that claimed four casualties ...
Cached Medicine News:Health News:Baby Underwent A Heart Surgery Inside The Womb 2Health News:Crohn's Patient Robert Hill’s greatest achievemen 2
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... and FLORHAM PARK, N.J. ... that once-daily naldemedine met its primary and secondary endpoints ... treatment of opioid-induced constipation (OIC) in adult patients with ... acting mu-opioid receptor antagonist (PAMORA). This is the third ... and key secondary endpoints. Study results showed ...
(Date:8/3/2015)... NESS ZIONA, Israel , August ... BVXV, TASE: BVXV) today announced it received the statistical analysis ... flu vaccine (M-001), administered in the BVX-005 phase II trial ... against future strains which did not exist at the time ... influenza (flu) strain that caused the epidemic in ...
Breaking Medicine Technology:Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
... Company Ltd. announced on August 23 the appointment of Dr. ... Menicon Holdings B.V. Dr. Choo will oversee the company,s Rose ... the company,s growing specialty lens portfolio. For the ... Adventus Technology Inc. and the Brien Holden Vision Institute (BHVI) ...
... the support of Key Opinion Leaders clearly linked to ... attention of KOLs is intensifying. But the changing regulatory ... and maintaining KOL and physician relationships. To ... Practices, LLC has published an updated MSL-focused report that ...
Cached Medicine Technology:Jennifer Choo Joins Menicon as Specialty Lens Clinical Manager 2Pharma Medical Science Liaison Outreach Shifting Away from Traditional Company Sales Regions 2
Double cuff electronic tourniquet....
... Safety. Convenience. Reliability. Cost. These are ... OR personnel, and administrators. With a special ... most practical elements of todays technology to ... , The A.T.S. 2000 Tourniquet uses ambient ...
... a revolutionary new addition to the Hall® ... PowerPro Battery System is the first and ... on the market. It is a full-function ... the requirements of large bone, small bone, ...
Stryker Instruments, the leader in cordless power, advances orthopaedics with the power, speed, versatility, reliability and performance through its heavy duty powered instruments....
Medicine Products: